Please login to the form below
beta thalassaemia
This page shows the latest beta thalassaemia news and features for those working in and with pharma, biotech and healthcare.
Celebrating the power of knowledge on International Thalassaemia Day 2022
In order to be born with the main form of thalassaemia – beta thalassaemia – a child has to inherit a copy of the faulty beta thalassaemia gene from both parents. ... also a carrier – eg if both parents have the faulty gene that causes beta
Latest news
-
bluebird bio splits to create new oncology firm 2seventy bio
progress with our product pipeline, including filing the US biologics licensing application for Beti-cel for beta-thalassaemia,” he added. ... Beti-cel (betibeglogene autotemcel) is a gene therapy for adult, adolescent and paediatric patients with
-
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
According to the companies, seven patients with transfusion-dependent beta thalassaemia (TDT), including three who have either a severe or b0/b0 genotype, were transfusion independent at the last follow-up.
-
bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
210 clinical studies of LentiGlobin for SCD, as well as the holds on the HGB-207 and HGB-212 studies of beti-cel for beta-thalassaemia. ... In relation to its beta-thalassaemia gene therapy Zynteglo, bluebird bio said this would be withdrawn from the
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
This includes CTX001 – an investigational gene therapy – which has already demonstrated promising early data in transfusion-dependant beta thalassaemia (TDT) and severe sickle cell disease (SCD) patients.
-
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
the FDA that we believe these results support lifting the clinical holds on our beta-thalassemia and sickle cell disease programmes,” he added. ... bluebird bio said that, based on the available data, it has initiated discussions with regulators to
More from news
Approximately 7 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day. Beta thalassaemia major is a serious, lifelong genetic blood disorder. ... At least 75, 000 children are born. with thalassaemia worldwide every year, of which 10, 000 have the debilitating form
-
20 for 2020 – Five pharma companies to watch
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Scientists discover new approach to treat brain tumours
- Recognising HIV Vaccine Awareness Day
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- UICC launches global ATOM Coalition to increase access to essential cancer medicines
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
- Roche shares new positive Ocrevus data for MS patients
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment
- MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients
- Creating an engaging experience for patients
- Mapping patient pathways – with a focus on patient-centricity
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
